COSCIENS Biopharma Inc.
CSCI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $16 | $7 | $10 | $6 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $2 | $0 | $2 | $2 |
| Inventory | $3 | $4 | $3 | $0 |
| Other Curr. Assets | $2 | $0 | $0 | $0 |
| Total Curr. Assets | $24 | $11 | $15 | $10 |
| Property Plant & Equip (Net) | $11 | $12 | $12 | $14 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $1 | $1 | $1 |
| Total NC Assets | $11 | $12 | $13 | $15 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $35 | $24 | $28 | $24 |
| Liabilities | – | – | – | – |
| Payables | $2 | $0 | $0 | $0 |
| Short-Term Debt | $0 | $1 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $3 | $5 |
| Other Curr. Liab. | $4 | $1 | $2 | $1 |
| Total Curr. Liab. | $7 | $1 | $7 | $8 |
| LT Debt | $2 | $1 | $0 | $2 |
| Deferred Rev, NC | $1 | $0 | $2 | $1 |
| Deferred Tax Liab, NC | $0 | $0 | $1 | $0 |
| Other NC Liab. | $12 | $0 | $0 | $18 |
| Total NC Liab. | $15 | $1 | $2 | $19 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $2 | $2 | $0 | $2 |
| Total Liabilities | $22 | $3 | $4 | $3 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $22 | $13 | $12 | $13 |
| Retained Earnings | -$12 | $4 | $8 | $5 |
| AOCI | -$1 | $4 | $4 | $4 |
| Other Equity | $4 | -$1 | $3 | $4 |
| Total Equity | $13 | $21 | $24 | $22 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $35 | $24 | $28 | $24 |
| Net Debt | -$14 | -$5 | -$10 | -$4 |